{"id":"high-dose-enoxaparin","safety":{"commonSideEffects":[{"rate":"1-10","effect":"Bleeding"},{"rate":"0.1-1","effect":"Thrombocytopenia"},{"rate":"5-10","effect":"Injection site hematoma"},{"rate":"1-5","effect":"Elevated transaminases"}]},"_chembl":{"chemblId":"CHEMBL1201476","moleculeType":"Oligosaccharide"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Enoxaparin is a low-molecular-weight heparin (LMWH) derived from unfractionated heparin. It works by potentiating antithrombin III, which inactivates coagulation factors Xa and IIa, thereby preventing thrombus formation. High-dose formulations are used in acute thrombotic conditions requiring more intensive anticoagulation.","oneSentence":"High-dose enoxaparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factors Xa and IIa.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:23:02.370Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome"},{"name":"Deep vein thrombosis prophylaxis and treatment"},{"name":"Pulmonary embolism treatment"},{"name":"Unstable angina"}]},"trialDetails":[{"nctId":"NCT06825416","phase":"PHASE3","title":"A Clinical Study of SHR-2004 Injection in Preventing Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Suncadia Pharmaceuticals Co., Ltd","startDate":"2025-03-16","conditions":"Prevention of Arterial and Venous Thrombosis","enrollment":1166},{"nctId":"NCT07140523","phase":"PHASE2","title":"A Study to Compare the Efficacy and Safety of SRSD107 and Enoxaparin in Adult Subjects Undergoing TKA","status":"RECRUITING","sponsor":"Sirius Therapeutics Co., Ltd.","startDate":"2025-09-16","conditions":"Venous Thromboembolism","enrollment":450},{"nctId":"NCT05255003","phase":"PHASE4","title":"STrategies for Anticoagulation in Patients With thRombocytopenia and Cancer-associated Thrombosis","status":"RECRUITING","sponsor":"Tzu-Fei Wang","startDate":"2022-08-29","conditions":"Cancer-associated Thrombosis, Thrombocytopenia","enrollment":50},{"nctId":"NCT04924322","phase":"PHASE2, PHASE3","title":"Catheter-Related Early Thromboprophylaxis With Enoxaparin Studies","status":"RECRUITING","sponsor":"Yale University","startDate":"2022-05-11","conditions":"Deep Venous Thrombosis","enrollment":258},{"nctId":"NCT04362085","phase":"PHASE3","title":"Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care","status":"COMPLETED","sponsor":"Unity Health Toronto","startDate":"2020-05-11","conditions":"COVID-19","enrollment":465},{"nctId":"NCT05752461","phase":"PHASE2","title":"SHR-2004 for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty","status":"COMPLETED","sponsor":"Beijing Suncadia Pharmaceuticals Co., Ltd","startDate":"2023-04-12","conditions":"Prevention of Venous Thromboembolism After Knee Arthroplasty","enrollment":353},{"nctId":"NCT04710732","phase":"PHASE4","title":"Individual Dose Adjustment of Low-molecular-weight-heparin by Thromodynamics Test.","status":"TERMINATED","sponsor":"Pirogov Russian National Research Medical University","startDate":"2021-03-01","conditions":"Venous Thromboembolism","enrollment":9},{"nctId":"NCT05819125","phase":"","title":"Comparison of the Risk of Venous Thromboembolism (i.e., Blood Clots in the Veins) and Bleeding Events in a Population of Obese Patients Receiving Higher-Dose or Extended-Duration Versus Conventional-Dose or Conventional-Duration of Prophylaxis (i.e., Preventive Treatment) With Enoxaparin","status":"TERMINATED","sponsor":"Sanofi","startDate":"2023-04-25","conditions":"Venous Thromboembolism","enrollment":21000},{"nctId":"NCT06153394","phase":"PHASE3","title":"Prolonged Hypercoagulability Following Major Liver Resection for Malignancy","status":"NOT_YET_RECRUITING","sponsor":"Western University, Canada","startDate":"2024-06-01","conditions":"Hepatic Disease, Surgery-Complications, Hypercoagulability","enrollment":50},{"nctId":"NCT05925140","phase":"PHASE1","title":"LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients","status":"UNKNOWN","sponsor":"Lebanese University","startDate":"2020-03-28","conditions":"COVID-19, Hospitalized COVID-19 Patients","enrollment":1000},{"nctId":"NCT04536363","phase":"PHASE2","title":"Cri Analog PG1 Effectiveness and Safety in Covid-19","status":"WITHDRAWN","sponsor":"Alonso Vera Torres","startDate":"2020-12-03","conditions":"Covid19","enrollment":""},{"nctId":"NCT03145675","phase":"PHASE4","title":"Optimizing the Anticoagulation Regimen of Enoxaparin During Percutaneous Coronary Intervention (OPTIENOX-PCI)","status":"COMPLETED","sponsor":"Peking Union Medical College Hospital","startDate":"2017-05-12","conditions":"Coronary Artery Disease, Percutaneous Coronary Intervention","enrollment":378},{"nctId":"NCT04808882","phase":"PHASE2","title":"ANTIcoagulation in Severe COVID-19 Patients","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-04-14","conditions":"Severe COVID-19 Pneumonia","enrollment":353},{"nctId":"NCT04110444","phase":"","title":"Sildenafil Citrate Added to Low Molecular Weight Heparin and Low Dose Aspirin in High-risk Pregnancy","status":"WITHDRAWN","sponsor":"Fayoum University Hospital","startDate":"2017-01","conditions":"High Risk Pregnancy","enrollment":""},{"nctId":"NCT04377997","phase":"PHASE2","title":"Safety and Efficacy of Therapeutic Anticoagulation on Clinical Outcomes in Hospitalized Patients With COVID-19","status":"UNKNOWN","sponsor":"Massachusetts General Hospital","startDate":"2020-05-15","conditions":"Cardiovascular Diseases, COVID-19","enrollment":300},{"nctId":"NCT05172115","phase":"PHASE3","title":"Catheter-Directed Thrombolysis Versus Anticoagulation Monotherapy in Intermediate-High Risk PE","status":"TERMINATED","sponsor":"Rajaie Cardiovascular Medical and Research Center","startDate":"2018-12-22","conditions":"Pulmonary Embolism, Pulmonary Thromboembolisms, Embolism, Pulmonary","enrollment":94},{"nctId":"NCT04401293","phase":"PHASE3","title":"Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients","status":"COMPLETED","sponsor":"Northwell Health","startDate":"2020-04-26","conditions":"Sars-CoV2, COVID","enrollment":257},{"nctId":"NCT04444700","phase":"PHASE3","title":"A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to (SARS-CoV-2) COVID-19 Pandemic","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2020-07-04","conditions":"COVID, Coronavirus Infection, Severe Acute Respiratory Syndrome","enrollment":465},{"nctId":"NCT02412982","phase":"PHASE4","title":"Evaluation of Venous Thromboembolism Prevention in High-Risk Trauma Patients","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2016-03","conditions":"Traumatic Injury, Venous Thromboembolism","enrollment":103},{"nctId":"NCT04345848","phase":"PHASE3","title":"Preventing COVID-19 Complications With Low- and High-dose Anticoagulation","status":"TERMINATED","sponsor":"University Hospital, Geneva","startDate":"2020-04-28","conditions":"COVID, Sars-CoV2","enrollment":160},{"nctId":"NCT02706249","phase":"PHASE2","title":"Study Of Weight-Based Versus Standard Dose Enoxaparin Thromboprophylaxis In High-Risk Hospitalized Cancer Patients","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2016-04","conditions":"Venous Thormboembolism","enrollment":50},{"nctId":"NCT02600260","phase":"NA","title":"Thromboprophylaxis in Pregnant Women in Hospital: A Prospective Clinical Trial","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2014-12-01","conditions":"Thrombophilia Associated With Pregnancy, Perioperative/Postoperative Complications, Venous Thrombosis","enrollment":7212},{"nctId":"NCT04520620","phase":"PHASE4","title":"Concentration-effect Relationship of Enoxaparin for Thromboembolic Prevention","status":"WITHDRAWN","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2020-05-02","conditions":"Sars-CoV2","enrollment":""},{"nctId":"NCT01763606","phase":"NA","title":"Enoxaparin Versus Aspirin in Patients With Cancer and Stroke","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2012-12-18","conditions":"Cancer Patients First-ever Acute Ischemic Stroke","enrollment":20},{"nctId":"NCT04408235","phase":"PHASE3","title":"High Versus Low LMWH Dosages in Hospitalized Patients With Severe COVID-19 Pneumonia and Coagulopathy","status":"UNKNOWN","sponsor":"Azienda Ospedaliero-Universitaria di Modena","startDate":"2020-06","conditions":"COVID, Pneumonia, Viral, Coagulation Disorder","enrollment":300},{"nctId":"NCT03805672","phase":"PHASE4","title":"Below Knee DVT Study","status":"TERMINATED","sponsor":"Oregon Health and Science University","startDate":"2014-09","conditions":"Deep Vein Thrombosis (DVT), Blood Clots","enrollment":4},{"nctId":"NCT01356992","phase":"PHASE3","title":"Patients With High-risk Acute Coronary Syndrome Without ST-segment Elevation","status":"TERMINATED","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2012-07","conditions":"Non ST Segment Elevation Myocardial Infarction, Unstable Angina","enrollment":62},{"nctId":"NCT00152971","phase":"PHASE3","title":"Dabigatran Etexilate vs Enoxaparin in Prevention of Venous Thromboembolism (VTE) Post Total Knee Replacement","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2004-11","conditions":"Arthroplasty, Replacement, Knee, Thromboembolism","enrollment":2615},{"nctId":"NCT01863134","phase":"PHASE4","title":"Clinical Effects of Eptifibatide Administration in High Risk Patients Presenting With Non-ST Segment Elevation Acute Coronary Syndrome (NSTE-ACS) Requiring Urgent Coronary Artery Bypass Graft Surgery in Short- and Long-Term Follow-up","status":"COMPLETED","sponsor":"Medical University of Silesia","startDate":"2005-01","conditions":"Non ST Elevation Myocardial Infarction","enrollment":140},{"nctId":"NCT00916669","phase":"PHASE2","title":"A Randomized Study to Evaluate the Effect of Two Different Doses of Enoxaparin Sodium in Combination With Standard Chemotherapy in Patients With Stage Small Cell Lung Cancer (SCLC)","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2008-07","conditions":"Small Cell Lung Cancer","enrollment":""},{"nctId":"NCT00113932","phase":"PHASE2","title":"UARK 2003-41: A Study of High-Dose Density Therapy in Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2003-12","conditions":"Multiple Myeloma","enrollment":140},{"nctId":"NCT00917254","phase":"PHASE2, PHASE3","title":"Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-05","conditions":"Venous Thromboembolism","enrollment":369},{"nctId":"NCT00913120","phase":"PHASE2, PHASE3","title":"Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement Surgery","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-05","conditions":"Venous Thromboembolism","enrollment":610},{"nctId":"NCT00790387","phase":"PHASE4","title":"Tirofiban and Enoxaparin in High Risk Coronary Intervention","status":"COMPLETED","sponsor":"The Prince Charles Hospital","startDate":"2004-06","conditions":"Acute Coronary Syndrome","enrollment":60},{"nctId":"NCT01063426","phase":"PHASE4","title":"Re-STOP DVT: Reload of High Dose Atorvastatin for Preventing Deep Vein Thrombosis in Statin Users","status":"UNKNOWN","sponsor":"Hallym University Medical Center","startDate":"2009-11","conditions":"Thrombosis, Prevention, Surgery","enrollment":180}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":23,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lovenox"],"phase":"marketed","status":"active","brandName":"High Dose Enoxaparin","genericName":"High Dose Enoxaparin","companyName":"Oregon Health and Science University","companyId":"oregon-health-and-science-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"High-dose enoxaparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factors Xa and IIa. Used for Acute coronary syndrome, Deep vein thrombosis prophylaxis and treatment, Pulmonary embolism treatment.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}